Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance

The pathophysiological implications of plasminogen activator inhibitor-1 (PAI-1) in HCV infection remain obscure. This prospective study evaluated 669 HCV patients, of whom 536 had completed a course of anti-HCV therapy and had pre-, peri- and post-therapy measurements of various profiles, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Ming-Ling, Lin, Yu-sheng, Pao, Li-Heng, Huang, Hsin-Chih, Chiu, Cheng-Tang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304196/
https://www.ncbi.nlm.nih.gov/pubmed/28211910
http://dx.doi.org/10.1038/srep42503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304196/
https://www.ncbi.nlm.nih.gov/pubmed/28211910
http://dx.doi.org/10.1038/srep42503

Ejemplares similares